Effects of HIV, Cocaine, and Prolonged ART Use on Subclinical Cardiovascular Disease

HIV、可卡因和长期使用 ART 对亚临床心血管疾病的影响

基本信息

  • 批准号:
    9897500
  • 负责人:
  • 金额:
    $ 162.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-06-01 至 2023-04-30
  • 项目状态:
    已结题

项目摘要

As the age of people living with HIV has been rising steadily due to the success of antiretroviral therapy (ART), and continued new infections, the number of people with HIV in the US is now 1.2 million and continues to rise. Since most older adults living with HIV were infected as young adults or in middle age, long-term effects of HIV and ART are now emerging. HIV/ART-associated comorbidities represent a major challenge for HIV-infected individuals. Of noninfectious comorbidities, coronary artery disease (CAD) has become one of leading causes of death among older people with HIV infection. In addition to CAD traditional risk factors, HIV and ART, cocaine use has been shown to be associated with CAD. In 1999, we received the first NIH grant in the US to investigate the effects of HIV and cocaine use on subclinical atherosclerosis, specifically HIV- associated cardiovascular comorbidity. Since then, 4 NIDA-funded studies by this team were conducted and a cohort of study participants, with/without HIV infection, with/without ART and with/without cocaine use, has been established and followed in Baltimore, Maryland for 17 consecutive years. Pursuing the goal of examining the individual and combined effects of HIV infection, long-term exposure to ART, chronic cocaine use, and other factors on subclinical CAD, we found that cocaine use may induce/accelerate subclinical CAD and other HIV-associated comorbidities. We recently identified several high priority research questions/hypotheses that deserve to be explored thorough collaborations with other investigators: (1) coronary plaque volume may be more sensitive to quantify factors associated with coronary plaque burden, (2) telomere length may be associated with HIV, cocaine use and aging, (3) Troponin T may be a maker for the degree of coronary plaque burden, and (4) homocysteine may be a potentially useful biomarker for HIV/cocaine associated comorbidities. The central objective for this U01 is to further examine whether and how cocaine use influences the HIV/ART- associated CAD and other comorbidities. The specific aims of this proposed study are: (1) to maintain and expand our existing cohort involving HIV/ART and cocaine-associated cardiovascular and other comorbidities as a platform for high priority research and as a platform for other scientific collaborations; (2) to examine longitudinally the effects of HIV, chronic cocaine use, and prolonged ART exposure on the presence, development and progression of CCTA-defined subclinical/clinical CAD, (3) to investigate whether cocaine use exacerbates the HIV-associated decline in cognitive function in HIV-infected cocaine users, (4) to investigate whether HIV and cocaine are associated with telomere shortening, and (5) to examine interrelationships between homocysteine (Hcy) and HIV/ART/cocaine-associated comorbidities. All the hypotheses proposed in this application have not been tested and are crucial to the scientific field of HIV/AIDS and substance abuse. The proposed study will make unique contributions to a better understanding of whether and how drug abuse exacerbates cardiovascular and other comorbidities in those with HIV and substance use disorder.
由于抗逆转录病毒治疗的成功,艾滋病毒携带者的年龄一直在稳步上升 (ART),以及持续的新感染病例,美国的艾滋病毒携带者人数现在为120万,而且还在继续 站起来。由于大多数感染艾滋病毒的老年人是在年轻或中年时感染的,从长期来看 艾滋病毒和抗逆转录病毒疗法的影响现在正在显现。艾滋病毒/抗逆转录病毒治疗相关的合并症是 感染艾滋病毒的人。在非感染性合并症中,冠状动脉疾病(CAD)已成为 导致感染艾滋病毒的老年人死亡的主要原因。除了CAD传统的危险因素外,艾滋病毒 而ART,可卡因的使用已被证明与CAD有关。1999年,我们收到了美国国立卫生研究院的第一笔拨款 美国将调查艾滋病毒和可卡因使用对亚临床动脉粥样硬化的影响,特别是艾滋病毒- 相关的心血管合并症。自那时以来,该团队进行了4项由NIDA资助的研究,并进行了 研究参与者的队列,有/没有艾滋病毒感染,有/没有抗逆转录病毒治疗和有/没有使用可卡因,有 已经在马里兰州的巴尔的摩成立并连续17年受到关注。追求审查的目标 艾滋病毒感染、长期接触抗逆转录病毒药物、长期使用可卡因以及 其他因素对亚临床冠心病的影响,我们发现可卡因的使用可以诱发/加速亚临床冠心病和其他 与艾滋病毒相关的合并症。我们最近确定了几个高度优先的研究问题/假设 值得与其他研究人员合作深入探索:(1)冠状动脉斑块体积可能 对量化与冠状动脉斑块负荷相关的因素更敏感,(2)端粒长度可能是 (3)肌钙蛋白T可能是冠脉斑块程度的标志物 同型半胱氨酸可能是艾滋病毒/可卡因相关合并症的潜在有用的生物标志物。 U01的中心目标是进一步研究可卡因的使用是否以及如何影响艾滋病毒/抗逆转录病毒治疗- 相关的冠心病和其他合并症。这项拟议研究的具体目的是:(1)维护和 扩大我们现有的涉及艾滋病毒/抗逆转录病毒药物和可卡因相关心血管疾病和其他共病的队列 作为高优先级研究的平台和其他科学合作的平台; 从纵向上看,艾滋病毒、长期使用可卡因和长期接触抗逆转录病毒药物对存在的影响, CCTA定义的亚临床/临床CAD的发展和进展,(3)调查可卡因是否使用 加剧艾滋病毒感染的可卡因使用者认知功能的下降,(4)调查 HIV和可卡因是否与端粒缩短有关,以及(5)检查相互关系 同型半胱氨酸(Hcy)与艾滋病毒/抗逆转录病毒药物/可卡因相关的共病之间的关系。中提出的所有假设 这一应用尚未经过测试,对艾滋病毒/艾滋病和药物滥用的科学领域至关重要。 拟议的研究将对更好地了解药物滥用是否以及如何滥用做出独特的贡献 加剧艾滋病毒携带者和药物使用障碍者的心血管和其他共病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SHENGHAN LAI其他文献

SHENGHAN LAI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SHENGHAN LAI', 18)}}的其他基金

The Impact of Cocaine Abstinence or Reduced Use on Radiomic Features of Noncalcified Coronary Plaques in HIV-Infected Cocaine Users with Silent Coronary Artery Disease
戒断或减少使用可卡因对患有无症状冠状动脉疾病的 HIV 感染可卡因使用者非钙化冠状动脉斑块放射学特征的影响
  • 批准号:
    9795066
  • 财政年份:
    2019
  • 资助金额:
    $ 162.13万
  • 项目类别:
Effects of HIV, Cocaine, and Prolonged ART Use on Subclinical Cardiovascular Disease
HIV、可卡因和长期使用 ART 对亚临床心血管疾病的影响
  • 批准号:
    10738836
  • 财政年份:
    2016
  • 资助金额:
    $ 162.13万
  • 项目类别:
Effects of HIV, Cocaine, and Prolonged ART Use on Subclinical Cardiovascular Disease
HIV、可卡因和长期使用 ART 对亚临床心血管疾病的影响
  • 批准号:
    9428415
  • 财政年份:
    2016
  • 资助金额:
    $ 162.13万
  • 项目类别:
Effects of HIV, Cocaine, and Prolonged ART Use on Subclinical Cardiovascular Disease
HIV、可卡因和长期使用 ART 对亚临床心血管疾病的影响
  • 批准号:
    8983355
  • 财政年份:
    2016
  • 资助金额:
    $ 162.13万
  • 项目类别:
Effects of HIV, Cocaine, and Prolonged ART Use on Subclinical Cardiovascular Disease
HIV、可卡因和长期使用 ART 对亚临床心血管疾病的影响
  • 批准号:
    10377889
  • 财政年份:
    2016
  • 资助金额:
    $ 162.13万
  • 项目类别:
Changes in Coronary Noncalcified Volume in Relation to Changes in Cocaine Use
冠状动脉非钙化体积的变化与可卡因使用变化的关系
  • 批准号:
    8656319
  • 财政年份:
    2013
  • 资助金额:
    $ 162.13万
  • 项目类别:
Changes in Coronary Noncalcified Volume in Relation to Changes in Cocaine Use
冠状动脉非钙化体积的变化与可卡因使用变化的关系
  • 批准号:
    8534993
  • 财政年份:
    2013
  • 资助金额:
    $ 162.13万
  • 项目类别:
Changes in Coronary Noncalcified Volume in Relation to Changes in Cocaine Use
冠状动脉非钙化体积的变化与可卡因使用变化的关系
  • 批准号:
    8823757
  • 财政年份:
    2013
  • 资助金额:
    $ 162.13万
  • 项目类别:
HIV Infection, Cocaine Use and Coronary Artery Disease in HIV+ African Americans
HIV 感染、可卡因使用和 HIV 非洲裔美国人的冠状动脉疾病
  • 批准号:
    7883687
  • 财政年份:
    2008
  • 资助金额:
    $ 162.13万
  • 项目类别:
HIV Infection, Cocaine Use and Coronary Artery Disease in HIV+ African Americans
HIV 感染、可卡因使用和 HIV 非洲裔美国人的冠状动脉疾病
  • 批准号:
    7620770
  • 财政年份:
    2008
  • 资助金额:
    $ 162.13万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 162.13万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 162.13万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 162.13万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 162.13万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 162.13万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 162.13万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 162.13万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 162.13万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 162.13万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 162.13万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了